Literature DB >> 24048480

Synthesis and biological evaluation of hydroxyl-substituted Schiff-bases containing ferrocenyl moieties.

Wansong Chen1, Weizhu Ou, Liqiang Wang, Yuanqiang Hao, Jiashun Cheng, Juan Li, You-Nian Liu.   

Abstract

Three new hydroxyl-substituted Schiff-bases containing ferrocenyl moieties were synthesized, and their antioxidant and anticancer activities were evaluated. Among the synthesized hydroxyl-substituted Schiff-bases, compound 1 containing both ferrocenyl and o-dihydroxyl groups exhibits the highest antioxidant and anticancer activities. Flow cytometric analysis showed that compound 1 is capable of disturbing the cancer cell cycle and inducing more cells to be arrested in G2 phase. The excellent biological activities of compound 1 are attributed to the presence of both ferrocenyl and o-dihydroxyl groups. The ferrocenyl moiety has dual functions in compound 1, i.e., increasing the lipophilicity and lowering the redox potentials of o-dihydroxyl groups. In addition, compound 1 could reversibly bind with HSA mainly via a mechanism involving the formation of complexes, in which hydrophobic interaction is the main acting force. Thus, compound 1 containing both ferrocenyl and o-dihydroxyl groups is a potential antioxidant with anticancer activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048480     DOI: 10.1039/c3dt51977e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  2 in total

1.  Design of ferrocenylseleno-dopamine derivatives to optimize the Fenton-like reaction efficiency and antitumor efficacy.

Authors:  Qianya Cheng; Tong Zhou; Qing Xia; Xiulian Lu; Heng Xu; Ming Hu; Su Jing
Journal:  RSC Adv       Date:  2021-07-22       Impact factor: 4.036

2.  Antimicrobial and antibiofilm activities of Cu(II) Schiff base complexes against methicillin-susceptible and resistant Staphylococcus aureus.

Authors:  Pooi Yin Chung; Ranon Earn Yueh Khoo; Hui Shan Liew; May Lee Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-09-24       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.